BioSante Pharma exploring its strategic alternatives

BioSante Pharmaceuticals has brought in Deutsche Bank to advise the company on its "strategic alternatives." The developer has advanced LibiGel, a topical therapy for female sexual dysfunction, into a late stage trial. BioSante has told investors that it hopes to gain an FDA approval on the treatment by 2010.

News of the Deutsche Bank move helped buoy shares of BioSante. The company announced in March that it had begun a Phase III trial on LibiGel.

- read the AP report

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.